Holdings of the Fund as of 6/18/2026
Total Number of Holdings (excluding cash): 50
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,351 |
$2,582,738.07 |
7.68% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
10,655 |
$2,306,700.95 |
6.86% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
19,970 |
$2,273,983.90 |
6.77% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
9,953 |
$2,273,165.67 |
6.76% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
39,646 |
$2,140,884.00 |
6.37% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
82,811 |
$1,272,805.07 |
3.79% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
6,445 |
$1,266,958.10 |
3.77% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
5,394 |
$1,196,227.38 |
3.56% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
44,715 |
$1,127,265.15 |
3.35% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,489 |
$1,124,107.07 |
3.34% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
3,185 |
$1,075,256.00 |
3.20% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
8,301 |
$1,027,331.76 |
3.06% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,824 |
$978,740.16 |
2.91% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,582 |
$964,925.08 |
2.87% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,746 |
$841,576.36 |
2.50% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
7,659 |
$752,266.98 |
2.24% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
9,431 |
$742,314.01 |
2.21% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
4,093 |
$662,779.49 |
1.97% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
11,505 |
$597,224.55 |
1.78% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
6,099 |
$481,699.02 |
1.43% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,944 |
$466,005.76 |
1.39% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
968 |
$445,473.60 |
1.33% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,380 |
$440,300.00 |
1.31% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
9,379 |
$421,961.21 |
1.26% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
7,071 |
$386,712.99 |
1.15% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,601 |
$383,948.55 |
1.14% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,954 |
$349,296.36 |
1.04% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,708 |
$314,796.20 |
0.94% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,624 |
$317,317.44 |
0.94% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,651 |
$300,746.22 |
0.89% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
12,227 |
$296,137.94 |
0.88% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
7,377 |
$256,387.64 |
0.76% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,922 |
$239,078.04 |
0.71% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,811 |
$238,653.58 |
0.71% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
14,532 |
$235,563.72 |
0.70% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
857 |
$235,572.16 |
0.70% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
7,368 |
$231,207.84 |
0.69% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
617 |
$214,753.02 |
0.64% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,847 |
$208,452.42 |
0.62% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
8,348 |
$202,939.88 |
0.60% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
3,174 |
$203,009.04 |
0.60% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,843 |
$197,440.59 |
0.59% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,876 |
$184,682.68 |
0.55% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,862 |
$168,380.66 |
0.50% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
6,305 |
$165,254.05 |
0.49% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,095 |
$155,281.40 |
0.46% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,924 |
$149,696.88 |
0.45% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
511 |
$142,103.99 |
0.42% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,252 |
$142,236.32 |
0.42% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
3,107 |
$137,888.66 |
0.41% |
| US Dollar |
$USD |
|
Other |
91,504 |
$91,504.27 |
0.27% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|